Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$31.00 – $68.95
86% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $76.03B | $70.61B | $53.27B | $76.57B | $79.84B | $68.28B | $62.44B | $61.35B |
| Cost of revenue | $67.03B | $3.07B | $49.14B | $57.34B | $67.31B | $63.54B | $56.65B | $56.98B |
| Gross profit | $9.01B | $67.55B | $4.13B | $19.23B | $12.54B | $4.74B | $5.79B | $4.38B |
| Gross margin | 11.8% | 95.7% | 7.8% | 25.1% | 15.7% | 6.9% | 9.3% | 7.1% |
| R&D | $281.0M | $301.9M | $263.0M | $259.6M | $291.2M | $0 | $272.8M | $348.6M |
| Operating income | $6.54B | −$627.0M | $2.11B | $16.98B | $10.27B | $2.34B | $3.31B | $2.05B |
| EBITDA | $8.47B | $1.84B | $4.61B | $20.81B | $13.16B | $4.65B | $6.06B | $5.12B |
| Net income | $5.15B | −$2.45B | −$733.0M | $14.96B | $9.30B | $919.0M | $1.34B | $3.28B |
| Net margin | 6.8% | -3.5% | -1.4% | 19.5% | 11.7% | 1.3% | 2.1% | 5.3% |
| EPS (diluted) | 5.04 | -2.42 | -0.64 | 12.98 | 10.36 | 1.09 | 1.69 | 4.28 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $66.7B | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $69.9B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
ARCELORMITTAL ORD NEW
No one on the platform currently holds AMSYF.
No tracked institution reports a position in AMSYF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-11-13 | $0.1500 | 2026-12-02 |
| 2026-08-07 | $0.1500 | 2026-09-09 |
| 2026-05-13 | $0.1500 | 2026-06-10 |
| 2026-02-13 | $0.1500 | 2026-03-18 |
| 2025-11-13 | $0.2750 | 2025-12-03 |
| 2025-05-16 | $0.2750 | 2025-06-11 |
| 2024-11-12 | $0.2500 | 2024-12-04 |
| 2024-05-16 | $0.2500 | 2024-06-12 |
| 2023-11-13 | $0.2200 | 2023-12-07 |
| Execution date |
|---|
No one on the platform has traded AMSYF yet.
| -2.03% |
| $52.8B |
| — |
| NVZMFNovozymes A/S | $60.60 | -0.08% | $28.3B | — |
| NVZMYNovozymes A/S | $63.24 | +1.38% | $29.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
| Ratio |
|---|
| 2017-05-26 | 1-for-3reverse |
Trading at 41.6× earnings vs its 7.4× historical median P/E.
Fair value ≈ $11.38 · price $63.65 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.